Abstract B016: Updated Safety, Efficacy and Biomarker Analysis from the Phase I Study of Givastomig, a Novel Claudin 18.2/4-1BB Bispecific Antibody, in Claudin 18.2 Positive Advanced Gastroesophageal Carcinoma (GEC)
Year: 2025
Type: conference-abstract
Source: Molecular Cancer Therapeutics
Authors: Samuel J. Klempner, Lin Shen, Farshid Dayyani, Jeremy Kratz, Xinjun Liang, Funan Liu, Zenning Wang, Laura Feller, Eugenia Girda, Hongming Pan, Sunnie Kim, Yanhong Deng, Ting Deng, Tianshu Liu, John Powderly, Kristen Spencer, Reva Schneider, Jordan Berlin, Claire (Cong) M. Xu, Christoph M. Ahlers, Xuejun M. Liu, Peter Sabbatini, Jinyoung Park, Yangmi Lim, Juyeun Jeon, Yuan Meng, Geoffrey Ku
Institutions: Massachusetts General Hospital, Peking University, Peking University Cancer Hospital, University of California, Irvine, UC Irvine Chao Family Comprehensive Cancer Center, University of Wisconsin–Madison, Hubei Cancer Hospital, First Hospital of China Medical University, Rutgers Cancer Institute, Sir Run Run Shaw Hospital, Zhejiang University, University of Colorado Cancer Center, Sun Yat-sen University, Sixth Affiliated Hospital of Sun Yat-sen University, Fudan University, Zhongshan Hospital, Carolina BioOncology Institute, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, New York University, Mary Crowley Cancer Research Center, Vanderbilt University Medical Center, ABL Bio (South Korea)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4415444399
Cites:
Cited by:
Related to: